Trial Profile

A Phase 1b/2 Study to Evaluate the Combination of Nivolumab (Anti PD1 Monoclonal Ab) With ADG106 (4-1-BB Agonist Monoclonal Ab) in Metastatic NSCLC After Progression With antiPD1 Therapy and Platinum-based Chemotherapy (ADIVO Lung Study)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jan 2022 According to an Adagene media release, first patient has been dosed in this trial.
01 Nov 2021 New trial record
27 Oct 2021 According to an Adagene media release, The trial will involve work under the Lung Cancer programme that is supported by the RIE2020 Open Fund- Large Collaborative Grant (OF-LCG) programme, administered by the Singapore Ministry of Health's National Medical Research Council (NMRC) and supported by the National Research Foundation Singapore.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com